Seres Therapeutics (MCRB) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 3, 2021 7:00 AM EDTSER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021
SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits
Microbiome analyses from SER-287 Phase 2b ulcerative colitis study anticipated in H2 2021
Continued clinical development progress with SER-155 and SER-301, next-generation rationally designed pipeline candidates
Conference call at 8:30 a.m. ET today
CAMBRIDGE,... More
